2022
DOI: 10.3389/fmed.2022.932171
|View full text |Cite
|
Sign up to set email alerts
|

Outcomes in AB0 Incompatible Living Donor Kidney Transplantation: A Case – Control Study

Abstract: BackgroundPatients waiting for a kidney transplant by far exceed available organs. AB0 incompatible living donor kidney transplantation (AB0i LDKT) represents an additional therapeutic strategy, but with higher risk for complications. We aimed at evaluating outcomes of AB0i LDKTs compared to compatible (AB0c) controls at our Institution.MethodsRetrospective matched case – control study (1:2) comparing AB0i vs. AB0c LDKTs from March 2012 to September 2021. Considered outcomes: graft function, acute rejection, s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 27 publications
(40 reference statements)
0
2
0
Order By: Relevance
“…ABOi kidney transplantation carries a higher risk of rejection compared to ABO compatible transplantation, most particularly antibody-mediated rejection [ 2 ]. To overcome this, both extensive pre-transplant conditioning and additional pre-transplant immunosuppressive therapy are required and include desensitization techniques such as antigen-specific immunoadsorption, B cell-depleting monoclonal antibodies (mainly rituximab), and intensified immunosuppression protocols.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…ABOi kidney transplantation carries a higher risk of rejection compared to ABO compatible transplantation, most particularly antibody-mediated rejection [ 2 ]. To overcome this, both extensive pre-transplant conditioning and additional pre-transplant immunosuppressive therapy are required and include desensitization techniques such as antigen-specific immunoadsorption, B cell-depleting monoclonal antibodies (mainly rituximab), and intensified immunosuppression protocols.…”
mentioning
confidence: 99%
“…To overcome this, both extensive pre-transplant conditioning and additional pre-transplant immunosuppressive therapy are required and include desensitization techniques such as antigen-specific immunoadsorption, B cell-depleting monoclonal antibodies (mainly rituximab), and intensified immunosuppression protocols. Such complex treatments expose children to a higher risk of bacterial and viral infections [ 2 ], post-transplant lymphoproliferative disease, and other neoplasias. Apheresis techniques require central venous lines in the absence of an arteriovenous fistula, especially in children on peritoneal dialysis or with pre-emptive transplantation, and these procedures can be complicated by infection, thrombosis, or bleeding, and so jeopardize future access to dialysis.…”
mentioning
confidence: 99%